SCHEMBL4175524

SCHEMBL4175524

CC[C@@H]1N(C(=O)c2ccccc2)C(=O)[C@]1(C)O[Si](CC)(CC)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
MAPK1 P28482 1/20 0.36
POLB P06746 1/20 0.35
TPSAB1 Q15661 1/20 0.35
TPSD1 Q9BZJ3 1/20 0.35
TPSG1 Q9NRR2 1/20 0.35
CRHBP P24387 2/20 0.35
CRHR2 Q13324 2/20 0.35
MAPT P10636 1/20 0.35
P2RY1 P47900 1/20 0.34
FOLH1 Q04609 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13778890 0.90 KMT2A (0.40) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4189538 0.82 KMT2A (0.36) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4192138 0.82 KMT2A (0.36) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4185469 0.81 KMT2A (0.36) KMT2AMEN1ALDH1A1NPSR1SMN1; SMN2
SCHEMBL6977783 0.69 KMT2A (0.43) KMT2AMEN1ALDH1A1POLBTPSAB1
SCHEMBL6977780 0.69 KMT2A (0.43) KMT2AMEN1ALDH1A1POLBTPSAB1
SCHEMBL6977776 0.69 KMT2A (0.43) KMT2AMEN1ALDH1A1POLBTPSAB1
SCHEMBL6151257 0.66 FOLH1 (0.37) KMT2AMEN1ALDH1A1SMN1; SMN2POLB
SCHEMBL6151262 0.66 FOLH1 (0.37) KMT2AMEN1ALDH1A1SMN1; SMN2POLB
SCHEMBL6151265 0.66 FOLH1 (0.37) KMT2AMEN1ALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure DAIICHI SANKYO COMPANY LIMITED (JP) 2009-07-23 US disclosed
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure DAIICHI SANKYO COMPANY LIMITED (JP) 2009-07-23 US disclosed
EP-1942109-A1 TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE Daiichi Sankyo Company, Limited (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186868-A1 Taxane Compound Having Azetidine Ring Structure ABCC1, AZI2, TPD52L2 KMT2A 950/4885MEN1 1676/4885ALDH1A1 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.